News Finding: PE patients may derive more benefit from 24 months anticoagulation pharmacotherapy compared to the standard 6 months. 
Paper Finding: Whether these should include systematic treatment with vitamin K antagonists, new anticoagulants or aspirin, or be tailored according to patient risk factors (including elevated D-dimer levels) needs further investigation.
News Context: PE patients may derive more benefit from 24 months anticoagulation pharmacotherapy compared to the standard 6 months. 
Paper Context: Our results suggest that patients such as those who participated in our study require longterm secondary prophylaxis measures. Whether these should include systematic treatment with vitamin K antagonists, new anticoagulants or aspirin, or be tailored according to patient risk factors (including elevated D-dimer levels) needs further investigation. Among patients with a first episode of unprovoked pulmonary embolism who received 6 months of anticoagulant treatment, an additional 18 months of treatment with warfarin reduced the composite outcome of recurrent venous thrombosis and major bleeding compared with placebo.